Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

New-Generation Hormone Therapies in Nonmetastatic Castration-Resistant Prostate Cancer: Why, Who, When.

Roviello G, Generali D.

Clin Genitourin Cancer. 2019 Feb 6. pii: S1558-7673(18)30797-3. doi: 10.1016/j.clgc.2019.01.020. [Epub ahead of print] No abstract available.

PMID:
30827924
2.

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.

Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, Sternberg CN.

N Engl J Med. 2018 Jun 28;378(26):2465-2474. doi: 10.1056/NEJMoa1800536.

3.

Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy.

Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, Arlen PM.

Clin Cancer Res. 2008 Jul 15;14(14):4526-31. doi: 10.1158/1078-0432.CCR-07-5048.

4.

Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.

Yu EY, Miller K, Nelson J, Gleave M, Fizazi K, Moul JW, Nathan FE, Higano CS.

J Urol. 2012 Jul;188(1):103-9. doi: 10.1016/j.juro.2012.03.008. Epub 2012 May 12.

5.

Treatment of Nonmetastatic Castration-Resistant Prostate Cancer.

Luo J, Beer TM, Graff JN.

Oncology (Williston Park). 2016 Apr;30(4):336-44. Review.

6.

Managing Nonmetastatic Castration-resistant Prostate Cancer.

Mateo J, Fizazi K, Gillessen S, Heidenreich A, Perez-Lopez R, Oyen WJG, Shore N, Smith M, Sweeney C, Tombal B, Tomlins SA, de Bono JS.

Eur Urol. 2019 Feb;75(2):285-293. doi: 10.1016/j.eururo.2018.07.035. Epub 2018 Aug 14. Review.

7.

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial.

Hara I, Yamashita S, Nishizawa S, Kikkawa K, Shimokawa T, Kohjimoto Y.

JMIR Res Protoc. 2018 Jul 27;7(7):e11191. doi: 10.2196/11191.

8.

Second-generation Androgen Receptor-targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?

Geynisman DM, Plimack ER, Zibelman M.

Eur Urol. 2016 Dec;70(6):971-973. doi: 10.1016/j.eururo.2016.05.026. Epub 2016 May 26. No abstract available.

PMID:
27238654
9.

Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.

Lodde M, Lacombe L, Fradet Y.

Urology. 2010 Nov;76(5):1189-93. doi: 10.1016/j.urology.2009.12.057. Epub 2010 Mar 29.

PMID:
20303155
10.

Efficacy of maximal androgen blockade versus castration alone in the treatment of advanced prostate cancer: a retrospective clinical experience from a Chinese medical centre.

Chen XQ, Huang Y, Li X, Zhang P, Huang R, Xia J, Chen N, Wei Q, Zhu YC, Yang YR, Zeng H.

Asian J Androl. 2010 Sep;12(5):718-27. doi: 10.1038/aja.2010.42. Epub 2010 Aug 9.

11.

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL.

Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Review.

PMID:
23859952
12.

Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells.

Liang Y, Mafuvadze B, Aebi JD, Hyder SM.

Onco Targets Ther. 2016 May 30;9:3223-32. doi: 10.2147/OTT.S105725. eCollection 2016.

13.

Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.

Smith MR, Antonarakis ES, Ryan CJ, Berry WR, Shore ND, Liu G, Alumkal JJ, Higano CS, Chow Maneval E, Bandekar R, de Boer CJ, Yu MK, Rathkopf DE.

Eur Urol. 2016 Dec;70(6):963-970. doi: 10.1016/j.eururo.2016.04.023. Epub 2016 May 6.

14.

Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.

Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.

J Urol. 2015 Dec;194(6):1537-47. doi: 10.1016/j.juro.2015.06.106. Epub 2015 Jul 18. Review.

PMID:
26196735
15.

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.

Nuhn P, De Bono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW, Sonpavde G, Sternberg CN, Yegnasubramanian S, Antonarakis ES.

Eur Urol. 2019 Jan;75(1):88-99. doi: 10.1016/j.eururo.2018.03.028. Epub 2018 Apr 16. Review.

PMID:
29673712
16.

Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer.

Pinto Á.

Cancer Biol Ther. 2014 Feb;15(2):149-55. doi: 10.4161/cbt.26724. Epub 2013 Nov 1. Review.

17.

Practice patterns and predictors of followup imaging after a negative bone scan in men with castration resistant prostate cancer: results from the SEARCH database.

Sourbeer KN, Howard LE, Moreira DM, Amarasekara HS, Chow LD, Cockrell DC, Hanyok BT, Pratson CL, Kane CJ, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Hernandez RK, Freedland SJ.

J Urol. 2015 Apr;193(4):1232-8. doi: 10.1016/j.juro.2014.11.014. Epub 2014 Nov 13.

18.

Emerging and second line therapies for the management of metastatic castration-resistant prostate cancer: the Australian perspective.

Parente P, Parnis F, Gurney H.

Asia Pac J Clin Oncol. 2012 Mar;8(1):31-42. doi: 10.1111/j.1743-7563.2011.01506.x. Review.

PMID:
22369442
19.

Stanniocalcin 2 overexpression in castration-resistant prostate cancer and aggressive prostate cancer.

Tamura K, Furihata M, Chung SY, Uemura M, Yoshioka H, Iiyama T, Ashida S, Nasu Y, Fujioka T, Shuin T, Nakamura Y, Nakagawa H.

Cancer Sci. 2009 May;100(5):914-9. doi: 10.1111/j.1349-7006.2009.01117.x. Epub 2009 Feb 26.

20.

Advances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy.

Pham T, Sadowski MC, Li H, Richard DJ, d'Emden MC, Richard K.

Exp Hematol Oncol. 2016 Jun 22;5:15. doi: 10.1186/s40164-016-0046-1. eCollection 2015. Review.

Supplemental Content

Support Center